Trial Profile

A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary) ; TLC 6740 (Primary) ; TLC 6740 (Primary) ; Itraconazole; Omeprazole; Voriconazole
Indications Diabetes mellitus; Lipodystrophy; Metabolic disorders; Non-alcoholic steatohepatitis; Obesity
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors OrsoBio

18 Dec 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
18 Dec 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2025.
18 Dec 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com